NAARI PTE. LIMITED
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Durable Goods, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about NAARI PTE. LIMITED
Live alerts from global media, monitored by Business Radar
2020-06-11 (biospectrumasia.com)
Naari Completes Acquisition of Andas From Intas Pharmaceuticals
Through the newly acquired portfolio, Naari will gain market access to USD900 million (per IQVIA data), accelerating its path to becoming one of the top women's health companies in the world
Read more
(vccircle.com)
Ascent-backed Naari to acquire drug applications portfolio to boost US biz
Ascent Capital-backed Naari Pharma Pvt. Ltd is set to acquire a portfolio of abbreviated new drug applications (ANDAs) from a
Read more